Skip to main content
Hualan Biological Engineering Inc. logo

Hualan Biological Engineering Inc. — Investor Relations & Filings

Ticker · 002007 ISIN · CNE000001JN8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,526 across all filing types
Latest filing 2026-03-29 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002007

About Hualan Biological Engineering Inc.

https://www.hualanbio.com

Hualan Biological Engineering Inc. is a biopharmaceutical enterprise specializing in the research, development, production, and commercialization of blood products and vaccines. The company’s portfolio is divided into two primary segments: plasma-derived therapeutics and viral vaccines. Key blood products include human albumin, intravenous immunoglobulin (IVIG), human coagulation factor VIII, and prothrombin complex. In the vaccine sector, the company produces seasonal influenza vaccines, including quadrivalent formulations, as well as hepatitis B and rabies vaccines. Hualan Biological Engineering operates advanced manufacturing facilities and plasma collection centers, focusing on high-quality standards and technological innovation in recombinant protein drugs and monoclonal antibodies to address critical medical needs in immunology, hematology, and infectious disease prevention.

Recent filings

Filing Released Lang Actions
独立董事候选人声明与承诺（刘永丽）
Board/Management Information Classification · 95% confidence The document is a declaration and commitment statement by an independent director candidate for a company's board. It contains detailed attestations about the candidate's qualifications, independence, and compliance with relevant laws and regulations. There are no financial statements, earnings data, or report summaries. The document is a formal statement related to board/management information, specifically about a director candidate's qualifications and commitments. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is short and focused on director candidacy, not a report or announcement of voting results.
2026-03-29 Chinese
独立董事提名人声明与承诺
Board/Management Information Classification · 95% confidence The document is a formal statement from the board nominating an independent director candidate, detailing compliance with various legal and regulatory requirements for the nomination. It includes declarations and commitments related to the candidate's qualifications and independence. There are no financial statements, earnings data, or report attachments. The document is not an annual report, earnings release, or any financial report but rather a governance-related announcement about board nominations. This fits the category of Board/Management Information (MANG), which covers announcements of changes or nominations in the company's board of directors.
2026-03-29 Chinese
2025年独立董事年度述职报告(张志谦)
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2025 Annual Work Report" for a specific individual, Zhang Zhiqian, detailing his duties, attendance, communication with audit and management, and overall evaluation during his tenure as an independent director. It is a narrative report on the director's activities and responsibilities rather than a financial report, earnings release, or regulatory filing. It does not contain financial statements or audit results but focuses on board/management information related to the director's role and performance. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is 2343 characters, which is consistent with a detailed management or board report rather than a brief announcement or a full annual report.
2026-03-27 Chinese
关于确认2025年度日常关联交易及预计公司2026年度日常关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the confirmation of the company's 2025 daily related party transactions and the forecast for 2026. It includes details about the nature of the transactions, amounts, related parties, pricing policies, and approvals by the board and independent directors. The document is a formal disclosure of related party transactions and their compliance with regulations, but it does not contain comprehensive financial statements or detailed financial performance data. It is not an annual or interim report, nor is it a management discussion or earnings release. It is a regulatory announcement about related party transactions, which fits best under the category of Regulatory Filings (RNS). The document length is about 4,832 characters, which is consistent with a detailed announcement but not a full report. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2026-03-27 Chinese
2025年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as an announcement regarding the 2025 annual profit distribution plan of the company 华兰生物工程股份有限公司. It details the profit distribution proposal, including dividend amounts, basis for distribution, and compliance with regulatory guidelines such as the China Securities Regulatory Commission's guidelines on cash dividends. The document includes audited profit figures, dividend payout ratios, and explanations on the rationale and impact of the dividend plan. It is an announcement of a dividend distribution plan rather than the full annual report or financial statements. The document length is about 4857 characters, which is relatively short and focused on the dividend plan. Therefore, it fits best under the category of Notice of Dividend Amount (DIV), which covers announcements of dividend amounts, payment dates, and details for shareholders.
2026-03-27 Chinese
2025年年度报告
Annual Report Classification · 100% confidence The document is titled "华兰生物工程股份有限公司2025 年年度报告全文" which translates to "Hualan Biological Engineering Co., Ltd. 2025 Annual Report Full Text." It contains detailed sections typical of an annual report, including company overview, financial data, management discussion and analysis, governance, and other comprehensive disclosures. The document length is 15,000 characters, indicating a full report rather than a brief announcement. It includes audited financial statements, management's discussion, and detailed business and financial information for the fiscal year 2025. There is no indication that this is merely an announcement or a presentation, nor is it a transcript or a regulatory filing of a different nature. Therefore, this document fits the definition of an Annual Report (10-K).
2026-03-27 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.